Eli Lilly & Co (LLY) - Oncology Revenue (I:ELCLFIMF)
Level Chart
Basic Info
|
Eli Lilly & Co (LLY) - Oncology Revenue is at a current level of 2.57B, up from 2.268B last quarter and up from 2.414B one year ago. This is a change of 13.32% from last quarter and 6.48% from one year ago. |
|
Oncology Revenue refers to the total revenue generated by Eli Lilly & Co from its products and treatments related to oncology within a specific reporting period. |
| Report | Fiscal.ai |
| Category | Segments & KPIs |
| Region | United States |
| Source | Fiscal.ai |
|
Data provided via Fiscal.ai |
Stats
| Last Value | 2.57B |
| Latest Period | Jun 2026 |
| Last Updated | Aug 5 2026, 08:57 EDT |
| Next Release | Oct 29 2026, 08:30 EDT (E) |
| Average Growth Rate | 16.75% |
| Value from Last Quarter | 2.268B |
| Change from Last Quarter | 13.32% |
| Value from 1 Year Ago | 2.414B |
| Change from 1 Year Ago | 6.48% |
| Frequency | Quarterly |
| Unit | USD |
| Adjustment | N/A |
| Download Source File |
Historical Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.57B |
| March 31, 2026 | 2.268B |
| December 31, 2025 | 2.607B |
| September 30, 2025 | 2.408B |
| June 30, 2025 | 2.414B |
| March 31, 2025 | 1.948B |
| December 31, 2024 | 2.552B |
| September 30, 2024 | 2.232B |
| June 30, 2024 | 2.159B |
| March 31, 2024 | 1.81B |
| December 31, 2023 | 1.884B |
| September 30, 2023 | 1.747B |
| June 30, 2023 | 1.671B |
| March 31, 2023 | 1.356B |
| Date | Value |
|---|---|
| December 31, 2022 | 1.651B |
| September 30, 2022 | 1.293B |
| June 30, 2022 | 1.369B |
| March 31, 2022 | 1.353B |
| December 31, 2021 | 1.409B |
| September 30, 2021 | 1.406B |
| June 30, 2021 | 1.554B |
| March 31, 2021 | 1.372B |
| December 31, 2020 | 1.516B |
| September 30, 2020 | 1.333B |
| June 30, 2020 | 1.269B |
| March 31, 2020 | 1.202B |
| December 31, 2019 | 1.080B |
News
Basic Info
|
Eli Lilly & Co (LLY) - Oncology Revenue is at a current level of 2.57B, up from 2.268B last quarter and up from 2.414B one year ago. This is a change of 13.32% from last quarter and 6.48% from one year ago. |
|
Oncology Revenue refers to the total revenue generated by Eli Lilly & Co from its products and treatments related to oncology within a specific reporting period. |
| Report | Fiscal.ai |
| Category | Segments & KPIs |
| Region | United States |
| Source | Fiscal.ai |
|
Data provided via Fiscal.ai |
Stats
| Last Value | 2.57B |
| Latest Period | Jun 2026 |
| Last Updated | Aug 5 2026, 08:57 EDT |
| Next Release | Oct 29 2026, 08:30 EDT (E) |
| Average Growth Rate | 16.75% |
| Value from Last Quarter | 2.268B |
| Change from Last Quarter | 13.32% |
| Value from 1 Year Ago | 2.414B |
| Change from 1 Year Ago | 6.48% |
| Frequency | Quarterly |
| Unit | USD |
| Adjustment | N/A |
| Download Source File |